BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 21, 2026
View BioWorld MedTech
Home » Neuronetics pops by over 60 percent on $94M IPO in the latest successful med-tech debut
To read the full story, subscribe or sign in.

Neuronetics pops by over 60 percent on $94M IPO in the latest successful med-tech debut

June 29, 2018
By Stacy Lawrence
Noninvasive depression device player Neuronetics Inc. has priced an IPO that hits the trinity of positive deal indicators: strong first-day upside, pricing above the anticipated range and increasing the number of shares offered. The Malvern, Pa.-based company saw its shares climb 63 percent on the first day of trading after offering 5.5 million shares, up from the expected 5 million. It priced the offering at $17 per share, above the anticipated range of $14 to $16.
Medical technology

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 21, 2026.
  • ALN-5288 lowers tau levels in preclinical models

    BioWorld Science
    Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
  • Neuropathy illustrated in legs and feet

    LIT-002 is strong candidate for autism and neuropathic pain

    BioWorld Science
    Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 21, 2026
  • 3D illustration of neutrophils

    New biomarker may improve RSV drug screening

    BioWorld
    Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing